Exagen Future Growth
Future criteria checks 1/6
Exagen is forecast to grow earnings and revenue by 16.6% and 13% per annum respectively. EPS is expected to grow by 18.1% per annum. Return on equity is forecast to be -252.9% in 3 years.
Key information
16.6%
Earnings growth rate
18.1%
EPS growth rate
Biotechs earnings growth | 35.3% |
Revenue growth rate | 13.0% |
Future return on equity | -252.9% |
Analyst coverage | Good |
Last updated | 19 Mar 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 75 | -15 | -8 | -8 | 4 |
12/31/2025 | 63 | -19 | -13 | -14 | 6 |
12/31/2024 | 54 | -24 | -18 | -18 | 6 |
12/31/2023 | 53 | -24 | -15 | -14 | N/A |
9/30/2023 | 52 | -32 | -30 | -29 | N/A |
6/30/2023 | 53 | -35 | -34 | -32 | N/A |
3/31/2023 | 46 | -45 | -37 | -33 | N/A |
12/31/2022 | 46 | -47 | -36 | -32 | N/A |
9/30/2022 | 45 | -40 | -37 | -32 | N/A |
6/30/2022 | 43 | -39 | -36 | -31 | N/A |
3/31/2022 | 48 | -31 | -28 | -25 | N/A |
12/31/2021 | 48 | -27 | -23 | -20 | N/A |
9/30/2021 | 48 | -23 | -19 | -18 | N/A |
6/30/2021 | 47 | -20 | -16 | -15 | N/A |
3/31/2021 | 43 | -17 | -16 | -15 | N/A |
12/31/2020 | 42 | -17 | -15 | -14 | N/A |
9/30/2020 | 40 | -17 | -15 | -14 | N/A |
6/30/2020 | 39 | -29 | -14 | -14 | N/A |
3/31/2020 | 41 | -31 | -11 | -11 | N/A |
12/31/2019 | 40 | -30 | -10 | -10 | N/A |
9/30/2019 | 40 | -31 | -8 | -8 | N/A |
6/30/2019 | 38 | -18 | -9 | -8 | N/A |
3/31/2019 | 35 | -18 | -8 | -8 | N/A |
12/31/2018 | 32 | -18 | -9 | -9 | N/A |
12/31/2017 | 27 | -33 | -12 | -11 | N/A |
12/31/2015 | 18 | -21 | N/A | -12 | N/A |
9/30/2015 | 18 | -21 | N/A | -11 | N/A |
6/30/2015 | 17 | -23 | N/A | -10 | N/A |
3/31/2015 | 15 | -17 | N/A | -10 | N/A |
12/31/2014 | 12 | -17 | N/A | -11 | N/A |
9/30/2014 | 9 | -23 | N/A | -11 | N/A |
6/30/2014 | 6 | -21 | N/A | -10 | N/A |
3/31/2014 | 4 | -19 | N/A | -8 | N/A |
12/31/2013 | 3 | -18 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: E08A is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: E08A is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: E08A is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: E08A's revenue (13% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: E08A's revenue (13% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: E08A is forecast to be unprofitable in 3 years.